# OnCo record destiny-breast05 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/destiny-breast05/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "destiny-breast05", "NCT04622319" ;
  schema:name "DESTINY-Breast05"@en ;
  schema:description "Enhertu cut recurrence or death by more than half compared with Kadcyla in women with cancer left after pre-surgery treatment, replacing the KATHERINE standard."@en ;
  schema:url <https://onco.cc/trials/destiny-breast05/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04622319>, <https://pubmed.ncbi.nlm.nih.gov/41370739/> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2020-12-04" ;
  onco:cancers <https://onco.cc/cancers/breast-her2-positive/>, <https://onco.cc/cancers/her2-positive-early-breast-cancer/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/topoisomerase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/trastuzumab-emtansine/> ;
  onco:companies <https://onco.cc/companies/daiichi-sankyo/>, <https://onco.cc/companies/astrazeneca/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-destiny-breast05-n-engl-j-med-2026/> .